To locally interfere with the CD47-SIRPα axis at the tumor site, we generated the so-called local inhibitory checkpoint monoclonal antibodies (licMABs), which consist of the endogenous SIRPα V-like domain linked to a mAb targeting CD33, a validated target antigen in AML [29] (Figure 2). The gene discussed is SIRPA; the disease is neoplasm.